Serveur d'exploration sur les relations entre la France et l'Australie - Analysis (Canada)

Index « Auteurs » - entrée « E. David-Neto »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
E. Dartigues < E. David-Neto < E. Dawe  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 2.
Ident.Authors (with country if any)Title
000C58 (2014) J. Yale [Canada] ; G. Bakris [États-Unis] ; B. Cariou [France] ; J. Nieto [Espagne] ; E. David-Neto [Brésil] ; D. Yue [Australie] ; E. Wajs [Belgique] ; K. Figueroa [États-Unis] ; J. Jiang [États-Unis] ; G. Law [États-Unis] ; K. Usiskin [États-Unis] ; G. Meininger [États-Unis]Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
000E73 (2013) J. Yale [Canada] ; G. Bakris [États-Unis] ; B. Cariou [France] ; D. Yue [Australie] ; E. David-Neto [Brésil] ; L. Xi [États-Unis] ; K. Figueroa [États-Unis] ; E. Wajs [Belgique] ; K. Usiskin [États-Unis] ; G. Meininger [États-Unis]Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

List of associated KwdEn.i

Nombre de
documents
Descripteur
1Adjustment period
1Adverse event
1Advisory panels
1Ahas
1Baseline
1Blood pressure
1Body weight
1Cana
1Chronic kidney disease
1Core treatment period
1Diabetes
1Diabetes care
1Diabetes mellitus
1Diabetes obes metab
1Discontinuation
1Dos
1Egfr
1Endpoint
1Fasting plasma glucose
1Genital mycotic infections
1Glucose
1Glucose excretion
1Glycaemic
1Glycaemic control
1Glycaemic rescue therapy
1Glycemic control
1Greater reductions
1Gure
1Hba1c
1Hypoglycaemia
1Hypoglycaemia episodes
1Inhibitor
1Insulin
1Janssen research development
1Last observation
1Least squares
1Lipoprotein cholesterol
1Ltration rate
1Median
1Metabolism
1Metabolism table
1Metformin
1Original article
1Original article diabetes
1Other reason
1Percent change
1Percent change difference
1Percent changes
1Placebo
1Placebo group
1Randomized
1Randomized subjects
1Renal
1Renal disease
1Renal function
1Renal function parameters
1Renal impairment
1Renal threshold
1Rescue therapy
1Research support
1Secondary endpoints
1Sodium glucose
1Standard deviation
1Standard error
1Statistical comparison
1Study drug
1Sulphonylurea
1Sulphonylurea agent
1T2dm
1Time point
1Transient changes
1Treatment groups
1Treatment period
1Urine

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Canada/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i -k "E. David-Neto" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i  \
                -Sk "E. David-Neto" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Canada
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    E. David-Neto
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024